Cite
HARVARD Citation
Jackson, D. et al. (2015). Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].